Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial
Author(s) -
James Whitehorn,
Nguyễn Văn Vĩnh Châu,
Phung Khanh Lam,
Duong Thi Hue Kien,
Nguyen Than Ha Quyen,
Nguyen Thi Thanh Tran,
Nguyen Thuy Hang,
Nguyen Thanh Truong,
Luong Thi Hue Tai,
Nguyen Thi Cam Huong,
Vo Thanh Nhon,
Ta Van Tram,
Jeremy Farrar,
Marcel Wolbers,
Cameron P. Simmons,
Bridget Wills
Publication year - 2015
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/civ949
Subject(s) - medicine , dengue fever , lovastatin , placebo , adverse effect , statin , clinical trial , randomized controlled trial , viremia , surgery , immunology , cholesterol , pathology , virus , alternative medicine
Dengue endangers billions of people in the tropical world, yet no therapeutic is currently available. In part, the severe manifestations of dengue reflect inflammatory processes affecting the vascular endothelium. In addition to lipid lowering, statins have pleiotropic effects that improve endothelial function, and epidemiological studies suggest that outcomes from a range of acute inflammatory syndromes are improved in patients already on statin therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom